Blue­bird's slow sick­le cell launch forces re­work of loan, putting cash run­way at risk

Blue­bird bio re­port­ed Wednes­day that just four pa­tients have start­ed the process for re­ceiv­ing its sick­le cell ther­a­py Lyf­ge­nia, en­dan­ger­ing a $50 mil­lion loan that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER